![](https://usercontent.one/wp/medimix.be/wp-content/uploads/sites/3/2023/06/els-vannieuwenhuyse-2.png)
Highlight 4 in gynaecologic cancer
Prof Els Van Nieuwenhuysen discussed the initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer,